ArticleBiosensors2023
Development of Electrochemical Immunosensors for HER-1 and HER-2 Analysis in Serum for Breast Cancer Patients.
Article in Biosensors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 53 citations in OpenAlex.
- MnFeFoods (Basel, Switzerland) · 2026Article
- Imide-linked phthalocyanine-based covalent organic framework for electrochemical sensing of human epidermal growth factor receptor 2.RSC advances · 2026Article
- Soluble isoforms of EGFR family in breast cancer: Advances and clinical relevance (Review).Oncology letters · 2026Review
- BreasTransNeXt: An Enhanced Multi-Module Vision Transformer For Early Breast Cancer Diagnosis.Journal of imaging informatics in medicine · 2026Article
- Review
- Attomolar electrochemical direct and sandwich immunoassays for the ultrasensitive detection of tomato brown rugose fruit virus.Plant methods · 2025Article
- Design of a Zn-based porphyrin MOF biosensor for fluorometric detection of HER2 as a breast cancer biomarker.RSC advances · 2025Article
- Innovative Methodologies for the Early Detection of Breast Cancer: A Review Categorized by Target Biological Samples.Biosensors · 2025Review
- HER-2-Targeted Electrochemical Sensors for Breast Cancer Diagnosis: Basic Principles, Recent Advancements, and Challenges.Biosensors · 2025Review
- A versatile gold leaf immunosensor with a novel surface functionalization strategy based on protein L and trastuzumab for HER2 detection.Scientific reports · 2025Article
- Early Detection, Precision Treatment, Recurrence Monitoring: Liquid Biopsy Transforms Colorectal Cancer Therapy.Current cancer drug targets · 2025Review
- Gold Nanoparticles: Multifunctional Properties, Synthesis, and Future Prospects.Nanomaterials (Basel, Switzerland) · 2024Review
- The portable stochastic sensor as a screening tool for simultaneous determination of HER-1 and CA 125 - a key factor in the rapid recognition of gastric cancer.Mikrochimica acta · 2024Article
- Screen-Printed Electrodes as Low-Cost Sensors for Breast Cancer Biomarker Detection.Sensors (Basel, Switzerland) · 2024Review
- Label-free and label-based electrochemical detection of disease biomarker proteins.ADMET & DMPK · 2024Review
- FeNC nanozyme-based electrochemical immunoassay for sensitive detection of human epidermal growth factor receptor 2.Mikrochimica acta · 2023Article
- Progress in Electrochemical Immunosensors with Alkaline Phosphatase as the Signal Label.Biosensors · 2023Review
- A Comprehensive Review on Electrochemical Nano Biosensors for Precise Detection of Blood-Based Oncomarkers in Breast Cancer.Biosensors · 2023Review
- Clinically Deployable Bioelectronic Sensing Platform for Ultrasensitive Detection of Transferrin in Serum Sample.Biosensors · 2023Article
- Comparative study of electrochemical-based sensors and immunosensors in terms of advantageous features for detection of cancer biomarkers.Turkish journal of chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
In this work, two human epidermal growth factor receptors, HER-1 and HER-2, were selected as biomarkers to enable the detection of breast cancer. Therefore, two biosensors were developed using gold sensor chips coupled with amperometric detection of the enzyme label horse radish peroxidase (HRP). The biosensors/immunosensors relied on indirect sandwich enzyme-linked immunosorbent assays with monoclonal antibodies (Ab) against HER-1 and HER-2 attached to the sensors to capture the biomarkers. Detection polyclonal antibodies followed by secondary anti-rabbit (for HER-1) and anti-goat (for HER-2) IgG antibody-HRP were then applied for signal generation. In buffer, the developed sensors showed limits of detections (LOD) of 1.06 ng mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.